TecTraum’s pro2cool® receives FDA Breakthrough Device Designation for the Concussions treatment
On November 03, 2021, TecTraum Inc., working to develop the world’s first point-of-care treatment for concussions, announced that the US Food and Drug Administration (FDA) has provided a Breakthrough Device to its flagship technology, pro2cool®. This system is a novel, non-invasive hypothermic therapy device designed to decrease the cruelty of concussion symptoms and let patients return to their pre-injury baseline sooner. It offers localised cooling for the head and neck to lower blood temperature before it enters the brain.
TecTraum CEO John Zak, MD, MBA, sa...
